N@N

iCAD to Present at Rodman & Renshaw 12th Annual Global Investment Conference

_{//science-technology.news-articles.net/content/2 .. aw-12th-annual-global-investment-conference.html}
^{Published in Science and Technology on Tuesday, September 7th 2010 at 6:11 GMT by Market Wire}  

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will be presenting a corporate update at the Rodman & Renshaw 12^th Annual Global Investment Conference on September 15, 2010 at 10:25 a.m. (Eastern time) being held at the New York Palace Hotel in New York City.

Management will also be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Growth Conference on September 14-15, 2010. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [ afields@lhai.com ] or contact your Rodman & Renshaw representative.

The presentation will be webcast live and archived for replay on the aInvestorsa section of the companya™s website at [ www.icadmed.com ] and at [ http://www.wsw.com/webcast/rrshq18/icad ].

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Companya™s first breast cancer detection product in 2002, more than 3,800 iCAD systems have been placed in healthcare practices worldwide. iCADa™s solutions aid in the early detection of the most prevalent cancers including breast, prostate, and colon, and, in the future, lung cancer. For more information, call (877) iCADnow or visit [ www.icadmed.com ].